Navigation Links
Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
Date:9/8/2009

BEERSE, Belgium, Sept. 8 /PRNewswire/ -- Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin((R)) (trastuzumab)*, a personalized medicine therapy, which was the first to target a specific type of breast cancer. Dr. Ullrich also led the development of the first drug created through gene cloning, a recombinant human insulin for treating diabetes which arguably marked the beginning of the biotechnology age. Dr. Ullrich, director for the Department of Molecular Biology, Max Planck Institute of Biochemistry in Germany, was presented with the Award during a ceremony at The Dr. Paul Janssen Research Center in Beerse, Belgium, where he received the $100,000 prize.

"Dr. Ullrich's pioneering research translated genomics-based discoveries into new treatments that improve the lives of millions of patients," said Harlan Weisman, M.D., chief science and technology officer, Medical Devices & Diagnostics, Johnson & Johnson. "The 2009 Award recognizes his commitment to advancing translational research, an approach that embodies the spirit of Dr. Paul Janssen, who himself pioneered the development of more than 80 different medicines."

Working at Genentech, Inc. more than 25 years ago, Ullrich developed genetically engineered human insulin, the first therapeutic derived from gene cloning. This insulin is structurally identical to the naturally occurring form, and acts more quickly and with fewer allergic reactions than insulin made from other sources. Ullrich and collaborators discovered later that decade that the neu/HER2 gene is amplified and overexpressed in more than 30 percent of invasive, or more aggressive, breast cancers. HER2 was chosen for the development of an entirely no
'/>"/>

SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
2. Johnson & Johnson Completes Acquisition of Cougar Biotechnology
3. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
4. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
5. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
6. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
7. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries
8. Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
9. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
10. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
11. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
(Date:12/19/2014)... 18, 2014 Today, TiFiber, ... pilot production facility and future company headquarters in ... innovative new materials that safely and effectively control ... because of its historic, strong support for manufacturing, ... attract leading edge, technology-based companies such as TiFiber. ...
(Date:12/19/2014)... 18, 2014 Ed Bilsky, Ph.D., vice ... Center for Excellence in the Neurosciences (CEN), and professor ... been selected as a member of the prestigious Dana ... neuroscientist from Maine to receive this honor. , ... entirely by the Dana Foundation. Its mission is ...
(Date:12/19/2014)... December 18, 2014 iLab Solutions, the ... appointment of Siri Bryant as the new Director of ... of Core Implementations. These two new leadership positions were ... service by ensuring that iLab continues to meet the ... last four years, iLab has been deployed at over ...
Breaking Biology Technology:Technology Innovations in Smart Fabrics (Technical Insights) 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... CAMBRIDGE, Mass., Dec. 17 Genzyme Corp.,(Nasdaq: ... and Drug Administration,(FDA) has approved a supplemental indication ... in combination with radioiodine to ablate,or destroy, the ... their,cancerous thyroids removed. Remnant ablation is a procedure ...
... GENEVA, Switzerland, Dec. 17 /PRNewswire-FirstCall/ - Anavex Life,Sciences ... of,Dr. Cameron Durrant to its Board of Directors. ... Global Strategic Marketing at Johnson,& Johnson (NYSE: ... privileged to welcome Dr. Durrant to our,Board," said ...
... England, December 17 , - New Deal ... its,Therapeutic Antibody Pipeline, Oxford Genome Sciences (UK) ... a strategic collaboration with Amgen to discover, develop ... cancer.,This new collaboration will enable OGeS to further ...
Cached Biology Technology:Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 3Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 4Anavex strengthens Board of Directors 2Anavex strengthens Board of Directors 3Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 2Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 3
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... professor of medicine at National Jewish Health, has ... lipids and related compounds that can inhibit inflammation ... by influenza and respiratory syncytial virus (RSV). Over ... several scientific papers describing a naturally occurring lipid ...
... bunch of inanimate chemical compounds, the nucleic and amino acids ... have put on quite a soap opera for biologists since ... A new study, a highlight in the March issue of ... In TV listings the series would be described this ...
... considered to be the principle vectors of West Nile virus ... summer. In addition, these mosquitoes may also serve as overwintering ... mosquito to egg, then larva, and then adult. To ... in mosquitoes in the field and in the lab, and ...
Cached Biology News:Does the villainous 'selfish' gene undermine genome's police? 2Does the villainous 'selfish' gene undermine genome's police? 3West Nile virus passes from female to eggs, but less so from larvae to adults 2
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The external laser upgrade for the Molecular Imager FX adds a 635 nm external laser; the 555 nm long pass filter is replaced with a 605 nm band pass filter to distinguish Cy5 from 532 nm excitable dy...
The HQ505, 20 OptiGreen filter for the Molecular Imager FX is a band pass filter used for detection of Cy2 and FITC with 532 nm excitation....
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
Biology Products: